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Abstract. We report a first in modeling and simulation of the effects of the HIV proteins on the
(caspase dependent) apoptotic pathway in infected cells. This work is novel and is an extension
on the recent reports and clarifications on the FAS apoptotic pathway from the literature. We
have gathered most of the reaction rates and initial conditions from the literature, the rest of the
constants have been computed by fitting our model to the experimental results reported. Using
the model obtained we have then run the simulations for the infected memory T cells, called also
latent T cells, which, at the moment, represent the major obstacle to finding a cure for HIV. We
can now report that the infected latent T cells have an estimated lifetime of about 42 hours from
the moment they are re-activated. As far as we know this is the first result of this type obtained
for the infected memory T cells.
1 Introduction
Apoptosis (or programmed cell death) is the process through which a multi-cellular organism
removes the cells that pose a threat locally (at the tissue level) or globally to the organism.
During the development of organisms, apoptosis is initiated in order to remove unneeded cells at
various developmental stages. Apoptosis is a form of cellular suicide, an attempt by an organism
to cleanly rid itself of cells that are unwanted, improperly formed, injured, infected, etc. It is a
vital process of multicellular organisms, because of this, the mechanisms of apoptosis are hard-
coded in all the cells of an organism and it can be executed in several ways; we will focus on
one particular signaling pathway, which utilizes members of the Caspase protein family. The
apoptotic pathway has been recently under a high degree of research focus [19,35,36] due to the
fact that it is estimated that more than 50% of the cancers result due to the inhibition or damage
in apoptotic signal transduction. Using the model from [19] we have recently simulated the FAS-
mediated apoptosis in [9] by using a deterministic waiting time algorithm from [26] which was
then modified and improved into a nondeterministic waiting time algorithm in [21]. The main
benefit for using the nondeterministic algorithm proposed by us is the fact that it is a discrete
simulation method (accounting for the discrete nature of the signal transduction pathways) as
opposed to differential methods and is also fast as opposed to the stochastic simulations such as
Gillespie’s algorithm (see [15,16]), without losing the nondeterministic behavior.
We are extending in the current paper the model from [21] to include HIV-1 proteins in the
nondeterministic discrete simulation of the effects of the HIV on the Fas-induced apoptosis. In
the following we will give a brief reason for the extension.
The HIV virus is currently causing a global epidemic according to the report published in
Geneva on November 21, 2006 by the World Health Organization. The virus infected roughly
1% of the global population with about 7.3% of the infected people dying in 2006.
† To whom correspondence should be addressed. E-mail: apaun@latech.edu
The HIV-1 virus, which is responsible for 99% of the HIV infections overall, has some re-
markable features. It infects cells from the immune system of the body: mainly CD4+ T cells,
but also monocytes and macrophages. The initial infection seems to be through the R5 virus
type that uses the co-receptor CCR5 for cell entry as reported in [33]. Reports have shown that
the R5 evolves through mutations into the X4 variant of HIV-1 (using co-receptor CXCR4) in
the infected individuals late during the course of the infection (see for example [33,11,27]). There
is a significant difference between the R5 and X4 variants of the virus, R5 is inducing apoptosis
in the bystander T cells while the X4 is responsible for the synctium formation (a multi nucleic
cell) which proceeds to the killing of even more immune cells. The fact that the X4 is usually not
present in the first stages of the HIV infection, but is more prevalent in the last stages of AIDS
suggests that a normal immune system could counteract the X4 strand effectively. So one could
derive that the immune system is first weakened by the R5 strand through apoptosis before the
X4 strand can “survive” and collapse it.
In this paper, we focus on simulating the effects on the Fas-induced apoptosis caused by
the HIV-1 strand R5 proteins. We report a simulation for the Fas-mediated pathway in HIV-1
infected cells. There are no other simulations of this type in existence. The HIV uses cellular
machinery to produce its proteins, in the creation of new virions. Therefore, when a T cell is
activated by the immune system, it can become infected by HIV, produce HIV proteins (and new
virus’) for a couple of days, then die by apoptosis. Yet, sometimes the CD4+ T cells will become
inactive after the HIV genome is incorporated into the cellular DNA. This results in a so-called
latent infection, which has been of major focus in recent research (reviewed in [17]). In [17]
the authors explain that latently infected cells are persistent in patients undergoing active HIV
treatment (such as HAART). It is clear that a better understanding of the latent cells will assist
biologists in the development of new treatments. In Section 2 we will highlight the key aspects
of our Fas-induced apoptosis model, Section 3 will describe the new simulation technique. In
Section 4 we review the role of HIV proteins in cell death and in Section 5 we present the results
our from model’s simulations and we finish with discussions in Section 6.
2 Fas-mediated signal cascade
There are several distinct death receptors, which, when activated, can lead to cellular apoptosis
through a tightly regulated molecular signaling cascade [3]. We have focused our previous efforts
on simulating the well-understood Fas-mediated pathway [21]. According to the literature [28]
and [20], understanding the complex signaling cascade of Fas-mediated apoptosis can assist in
the creation of remedies for cancer and autoimmune disorders. In this paper we provide an
expansion of our previous model, described in [21], in order to decipher and predict the behavior
of HIV-infected cells. But first, we discuss the Fas-mediated signaling pathway.
There are two versions of the Fas-mediated pathway [32], they are generally referred to as the
type I and type II pathways. Both pathways begin with the Fas ligand binding to the Fas receptor
(CD95) on the cell membrane. The ligand forces a conformational change of the Fas receptor,
which then goes on to recruit the Fas-associated death domain (FADD). Once FADD is bound
(up to three FADD per Fasl-Fas site), Procaspase 8 and FLIP can be competitively recruited to
the death domain. FLIP is an inhibitor of the pathway, in that its binding to the death domain
removes binding sites for Procaspase 8. The recruitment of at least two Procaspase 8 molecules
can lead to cleavage into active Caspase 8 form. The divergence in the two pathways occurs after
active Caspase 8 is in the cytoplasm; the end result of both pathways is the cleavage of Procaspase
3 into active Caspase 3. If the initial concentration of Caspase 8 is large enough, Caspase 3 is
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directly phosphorylated by Caspase 8 (type I pathway). Otherwise, Caspase 8 truncates Bid,
which binds with two Bax molecules enabling the release of cytochrome c from the mitochondria
(type II pathway). Bcl-2 can hinder the release of cytochrome c (thus, inhibiting apoptosis) by
binding to Bid, tBid, Bax or the tBid:Bax molecular complexes. Once released, cytochrome c
binds to Apaf and ATP before recruiting and activating Caspase 9. The active Caspase 9 can
then go on to activate Procaspase 3. XIAP can prohibit apoptosis by binding to Caspase 9, thus
preventing the phosphorylation of Caspase 3.
Though the molecules of the Fas-mediated pathways (type I and type II) have been analyzed
experimentally (pro- and anti-apoptotic), we believe the only way to understand the dynamics of
the complex apoptotic system is through computer simulations. In [19] and [21], three different
modeling methods are employed that yield results similar to experimental observations. We use
our ideas from [21] and modify the model to incorporate the functions of HIV proteins.
3 The membrane system model
There are three schools of thought on modeling molecular interactions. Microscopic chemistry
- that is, the consideration of molecular dynamics for every single molecule in the system (po-
sition, momenta of atoms, etc.) - is computationally intractable; the time scale involved in the
simulations, uncertainty about cellular components, and the number of atoms involved are fac-
tors that make this approach impossible to implement in a computational system. Differential
equations are the macroscopic approach. This approach has been applied to the Fas pathway
previously in [19].
We believe that differential equations are not the best approach for modeling signal cascades
involving low numbers of molecules. We discussed this in general for the Fas-mediated pathway
in [21] and now we expand our ideas into the realm of HIV proteins, where proteins like Vpr
are at a level of only ∼700 molecules upon viral infection [6]. Our approach, referred to as
mesoscopic chemistry, is similar to the microscopic approach. However, we ignore insignificant
molecules, like water and non-regulated parts of the cellular machinery, and we do not directly
model the position and momenta of the molecules, but we model molecular interactions using
statistical equations governing how often and which molecules interact. Our approach allows finer
modeling of a molecular system than the macroscopic approach, and yet it is more tractable
than the microscopic approach.
The membrane system paradigm is based on the compartmental structure found in cells.
Each compartment has different rules and objects, and the system evolves as the rules are
carried out based on the objects in the compartments. As we are modeling molecules in a cell,
it is a natural approach to use a membrane system.
We provide now all of the different types of rules (reactions) our membrane system can
simulate:
Transformation, complex formation and dissociation rules:
(1) [ a ]l → [ b ]l
(2) [ a, b ]l → [ c ]l
(3) [ a ]l → [ b, c ]l
(4) [ a, b, c ]l → [ d ]l
(5) [ a ]l → [ b, c, d ]l where a, b, c, d ∈ Σ and l ∈ L.
These rules are used to specify chemical reactions taking place inside a compartment of type
l ∈ L, more specifically they represent the transformation of a into b; the formation of a
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complex c from the interaction of a and b; and the dissociation of a complex a into b and c.
The rules of type (4) model the formation of a complex d from the interaction of 3 molecules:
a, b and c and the rules of type 5 model the dissociation of the complex a into 3 molecules
b, c, and d.
Diffusing in and out:
(6) [ a ]l → a [ ]l
(7) a [ ]l → [ a ]l where a ∈ Σ and l ∈ L.
When chemical substances move or diffuse freely from one compartment to another we use
these types of rules, where a moves from or to a compartment of type l.
Binding and unbinding rules:
(8) a [ b ]l → [ c ]l
(9) [ a ]l → b [ c ]l where a, b, c ∈ Σ and l ∈ L.
Using rules of the first type we can specify reactions consisting in the binding of a ligand
swimming in one compartment to a receptor placed on the membrane surface of another
compartment. The reverse reaction, unbinding of substance from a receptor, can be described
as well using the second rule.
Recruitment and releasing rules:
(10) a [ b ]l → c [ ]l
(11) c [ ]l → a [ b ]l where a, b, c ∈ Σ and l ∈ L.
With these rules we represent the interaction between two chemicals in different compart-
ments whereby one of them is recruited from its compartment by a chemical on the other
compartment, and then the new complex remains in the latter compartment. In a releasing
rules a complex, c, located in one compartment can dissociate into a and b, remaining a in
the same compartment as c, and b being released into the other compartment.
Our interest in the simulator lies in the molecular multiplicity evolution over time. Our rules
are carried out at varying lengths of time, obeying the Law of Mass Action - that is, the reac-
tion rate depends proportionally on the multiplicities of the reactants. Therefore, the number of
reactants for a given reaction logically governs the speed at which that reaction will occur. In
our model, the time for each reaction to occur is calculated (Waiting Time or WT), and after
sorting all waiting times, the reaction with the least waiting time is applied once (reactants de-
creased/products increased by one molecule). The simulation clock is aggregated (τ = τ+WT),
and the WT of each the reaction affected by the applied reaction (i.e., number of reactants of
reaction changed) are recalculated. The process continues until the desired simulation time has
been reached.
To calculate the waiting time for each reaction r we have an associated reaction rate con-
stant1. For each reaction r we pre-compute a kinetic constant constr: constr =
kr
V i−1×N i−1
where
V is the volume of the system, N is Avogadro’s constant (6.0221415×1023) and i is the number
of reactants involved in the reaction. The time needed for the reaction r to finish will then be
computed in the following way: wtr =
1
constr∗|A|∗|B|
where |A| and |B| represent the multiplicities
of the two reactants A,B of the reaction r. On the other hand, if the reaction simulated is a
dissociation or other first order reaction involving one reactant, A, then the time is computed
as wtr =
1
kr∗|A|
. Now we shall discuss how the HIV proteins interact with the Fas-mediated
pathways (type I and type II), and the method with which we set up a simulation of these
effects.
1 Some of the reaction rate constants are from [19] and the HIV protein associate rates are derived from various
sources
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4 The roles of HIV proteins in apoptosis
The onset of AIDS is associated with the loss of immune function, due to the death of CD4 T
cells (among others). As part of our simulation, we have focused on the mechanisms through
which an infected cell is kept alive in order to produce new provirus’, aiding in the spread of the
infection.
The method through which an HIV virus infects a cell is well understood. A spike on the
virus (the gp120 molecule) binds to the CD4 receptor of primary T cells, and in conjunction with
subsequent binding to a coreceptor (CCR5 or CXCR4), a path is opened for the virus to inject
its contents into the cell [8] and [39]. Reverse transcriptase translates the RNA into DNA and
the code is implanted into the cells own DNA for future production, once the cell is activated.
During this time, the immune system fails to detect and destroy the infected cell. HIV proteins
that were packaged in the virion with the RNA interact with various signaling cascades (e.g., Fas
pathway) within the cell preparing it for viral reproduction while avoiding annihilation by the
immune system. It is not until the immune system activates the T cell that viral reproduction
occurs.
In this study, we focus on the specific functions of the HIV proteins related to the apoptosis of
CD4 T cells; reviews are found in [31], [29] and [2]. The functions of some of these proteins are still
up for debate, however, we have pooled the collective knowledge of the biological community in
order to categorize and model the described functions of various HIV proteins. For an illustration
of the FAS-mediated apoptosis pathway and the involvement of the HIV proteins, we refer the
reader to Fig. 1.
The HIV protein, Tat, has shown both pro-apoptotic and anti-apoptotic behavior. In [4], the
authors were able to show that Tat expression in the cell leads to up-regulation of Procaspase
8 (proapoptotic molecule). Tat has been associated with upregulation of Bcl-2 (antiapoptotic
molecule) [14]. Conversely, [31] argues that Tat downregulates Bcl-2, resulting in increased sen-
sitivity to the Fas-mediated type II pathway. Tat has also been implicated in the upregulation of
the Fas ligand in infected cells [4] and [40]. However, the upregulation is assumed to be a mech-
nism to destroy CTLs (thus, keeping the cell alive) and bystander cells through Fas-mediated
apoptosis, the increase of Fas ligand does not appear to affect apoptosis of the infected cell [31].
Another HIV protein, Vpr, has been implicated in both prohibiting and assisting apoptosis.
Since Vpr is located in the virions, a low concentration is avaible early in the infected cell life-
cycle (assumed to be 700 molecules according to [6]). At low multiplicity, Vpr has been shown
to prohibit apoptosis by up-regulating Bcl-2 and down-regulating Bax (proapoptotic molecule)
[12].
HIV protease, which is responsible for cleaving the proteins created from the viral genetic
code, has also been shown to affect the signaling cascade in apoptosis. The HIV protease has
been shown to cleave Bcl-2 into a deactive state [34], while it is also responsible for cleaving
Procaspase 8 into active Caspase 8 form [24], both events lead to an increased susceptibility for
Fas-mediated apoptosis.
The HIV RNA travels to the nucleus and becomes incorporated into the cellular genetic code.
While the T cell is activated by the immune system, the HIV proteins are manufactured through
the cellular machinery (transcription into HIV RNA and translation through the ribosomes in
the cytoplasm). The simulator makes stochastic choices on where to send the Tat, Vpr, and HIV
Protease (cytoplasm, mitochondria, or extracellular). Using the information on the three HIV
proteins, we were able to create 11 new rules for our simulator. Our results are discussed below.
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Fig. 1. The HIV proteins affect the Fas-mediated pathway in various ways. The picture illus-
trates the type I and type II pathways. We consider the activation of Procaspase 3 to be the
end of the apoptotic pathway (signifying the death of the cell). The type I pathway involves di-
rect activation of Procaspase 3 by Caspase 8. The type II pathway requires signal amplification
through the release of cytochrome c from the mitochondria resulting in Caspase 9 activating
Procaspase 3. Tat upregulates Procaspase 8 and Bcl-2, but it can also down-regulate Bcl-2. Vpr
upregulates Bcl-2 and downregulates Bax. HIV protease can cleave Bcl-2 into an inactive form
and it can also cleave Procaspase 8 into active Caspase 8.
5 Results of the Infected Model
Based on the rules in Appendix A we simulated two different version of T cells. What we refer to
as the ”Non-latent” is a simulation of the T cell just after the contents of a virion have infected
it, so there is Vpr active in the cytoplasm and the RNA is on its way to being incorporated into
the DNA of the active CD4 cell. We call the second simulation method ”Post-latent”, which is
a simulation of the reactivation of an infected, but latent CD4 cell. We seek to achieve greater
understanding on the nature of latently infected cells.
As we consider activation of Procaspase 3 to be an indication of the onset of apoptosis, we
see in Fig. 2 that both the Post-latent and Non-latent cells die in approximately two days. Our
simulations do indicate that reactivated latent cells will die more quickly than freshly infected
cells. The lack of Vpr molecules in the latent cells is most likely the cause, as the anti-apoptotic
effect of the protein would not be available. Also in Fig. 2 we show the truncation of Bid, a
necessary step in the induction of the type II pathway. Active Caspase 8 is responsible for the
truncation of Bid, so we again see the affects of the increased rate of Caspase 8 activation. The
amplification of the signal through the mitochondria occurs earlier in the Post-latent than in
the Non-latent simulation.
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Fig. 2. On the left, we see cell death for the latently infected cell occuring in 42 hours and
freshly infected cell dying in 49 hours. On the right, we illustrate the rates of truncations for
Bid, a signal for the induction of the type II pathway.
In an HIV infected cell, Procaspase 8 can be activated by two ways, interactions with FADD
or HIV Protease. The upregulation of Procaspase 8 by Tat increases the activation rate of
Procaspase 8 (because it increases the chance of Procaspase 8 interacting with the existing
FADD or HIV Protease molecules). As the number of molecules of Fas ligand is the same
between both simulations, the increased rate of apoptosis is due to the creation and activity of
HIV Protease and Tat. In Fig. 3, we show the activation of Procaspase 8 and Procaspase 9 for
each of the simulations.
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Fig. 3. These graphs show the increase of active Caspase 8 and Caspase 9 molecules over the
entire simulation run. On the left is the Post-latent simulation and on the right is the Non-latent
run.
We next seek to determine whether the Procaspase 3 is being activated through the type
I or the type II pathway. According to our rule set, an interaction between Procaspase 3 and
active Caspase 8 or Caspase 9 can have two outcomes, resulting in activation of the Procaspase
3 molecule or not. Interestingly, it appears that the two pathways work together to annihilate
the cell. The Non-latent simulation shows the first interaction of a molecule of Procaspase 3
occurs with a Caspase 8 molecule just after 10 hours into the run. It isn’t until a 14 hours
later (24.5 hours into the run, allowing for signal transduction through the mitochondria) that
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we begin to see Procaspase 3 interactions with active Caspase 9. As we have shown in [21],
given a sufficiently high concentration of procaspase 8 in the T cell, there is no need for signal
amplification. However, the initial level of Procaspase 8 in our model reflects Jurkat T Cells [19],
and we are seeing cooperation between Caspase 8 and Caspase 9 leading to cellular apoptosis.
In Fig. 4 we get an overall image of the effects of both pathways on Procaspase 3 activation.
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Fig. 4. These graphs show the type I and type II pathways working together to activate Procas-
pase 3 during the non-latent simulation. The Type I interactions are active Caspase 8 binding
with Procaspase 3, and the Type II interactions are Caspase 9 binding with Procaspase 3. On
the right we see the overall picture for the whole three days of simulation. On the left we can see
a window of one whole minute from the simulation (from 26 hours to 26 hours and 1 minute).
We find similarities in the Procaspase 3 activation between the Non-latent and Post-latent
simulation runs. In the Post-latent run, we see type I interactions occur about 6 hours into
the simulation, while type II molecular binding occurs after 17 hours (11 hours after the type
I interactions). Fig. 5 show us an the overall interactions between Procaspase 3 with active
Caspase 8 or Caspase 9.
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Fig. 5. These graphs show the type I and type II pathways working together to activate Procas-
pase 3 during the post-latent simulation. The Type I interactions are active Caspase 8 binding
with Procaspase 3, and the Type II interactions are Caspase 9 binding with Procaspase 3. On
the right we see the overall picture for the whole three days of simulation. On the left we can see
a window of one whole minute from the simulation (from 26 hours to 26 hours and 1 minute).
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The graphs in Fig. 4 and 5 imply that there are more interactions in the type I pathway. This
does not necessarily mean that the type I pathway has a greater responsibility in activation of
Caspase 3 than the type II pathway. Caspase 3 activation is a two step process. First, Caspase 8
or 9 binds to the Procaspase 3 molecule, then after a period of time the binding ends with either
an active Caspase 3 or the original Procaspase 3 molecule. Technically, based on the kinetic
rates and the concentration of molecules involved, Caspase 8 can stay binded to Procaspase 3
for longer than Caspase 9. Therefore, though it appears that Caspase 8 binds to Procaspase 3
more frequently, it might not be the case that this results in more activation of Caspase 3 via
Caspase 8 than Caspase 9. The graphs illustrate this possibility by the fact that you see constant
jumps for the type II interactions (Caspase 9 and Procaspase 3), which implies less waiting time
during the binding period.
6 Discussion
Based on the biological evidence from the literature, we were able to construct a simulation of
the effects of HIV proteins on the Fas-mediated apoptosis pathway. We feel that our unique
approach provides insight into the molecular dynamics of the Fas pathway. Our simulator leads
to apoptosis in approximately two days, which is in agreement with observed results. But, we
have shown that cooperation between the type I and type II pathway seems to be the method
of the cell death.
In this preliminary simulator, we have focused primarily on the difference between reactivated
latent cells and actively infected cells, but we are looking to refine and expand our technique.
We will apply new information on the nature of latent HIV infected cells as it becomes available.
However we will also explore alternative HIV models. For instance, it would be interesting to
model the effects HIV proteins on bystander cell apoptosis. The type 1 HIV has been implicated
in reducing T cell levels by not only destroying the cell it invades, but through the killing of so-
called bystander (uninfected) cells [14]. Various mechanisms have been debated as to the means
through which the virus causes the destruction of the bystander (uninfected) cells. Along with
Fas-induced apoptosis, other possible mechanisms for bystander cell death are reviewed in [31],
[29] and [2]. Upon being exocytised by an infected cell, several distinct types of HIV proteins
can affect neighboring bystander cells.
Soluble and membrane-bound Env can bind to the CD4 receptor of bystander cells (as is the
case during infection). Along with subsequent binding to a co-receptor, it can induce apoptosis.
In [10] and [5], it has been shown that ligation of the CD4 receptor by Env, is sufficient to
increase apoptosis in bystander cells. The reasons for increased apoptosis following Env-CD4
binding can be attributed to Bcl-2 down-regulation [18], increased Caspase 8 activation [1], and
upregulation of Fas [25], FasL and Bax [31].
Extracellular Tat can be endocytised by a bystander cell, resulting in pro-apoptotic behavior.
The addition of Tat to a culture of uninfected cells has been shown to increase apoptosis [23].
Endocytised Tat can up-regulate levels of Caspase 8 [4] and increase expression of the Fas ligand
[31], similar to its effects in infected cells. Extracellular Vpr can disrupt the mitochondrial
membrane, leading to increased translocation of cytochrome c [31].
Lastly we would like to note the fact that the experimental information about the latent
HIV infected T cells is scarce, the main reason being the fact that these cells are found in small
numbers in vivo, thus it is rather hard to obtain sufficient numbers for experiments in vitro. We
hope that our results will help guide the researchers in the lab and we are looking forward to
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experimental results about these enigmatic cells that will suggest improvements and refinements
of our model.
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A The Model
Our model consist of the following P system:
Π = (Σ,L, µ,M1,M2,M3,M4,M5, R1, R2, R3, R4, R5)
where:
– In the alphabet we represent the proteins and complexes of proteins involved in the signalling
transduction:
Σ = {HIVRNA, Tat, Vpr, HIV Protease, FASL, FAS, FASC, FADD, FASC-FADD, FASC-
FADD2, FASC-FADD3, FASC-FADD2-CASP8, FASC-FADD3-CASP8, FASC-FADD2-FLIP,
FASC-FADD3-FLIP, FASC-FADD2-CASP82, FASC-FADD3-CASP82, FASC-FADD2-CASP8-
FLIP, FASC-FADD3-CASP8-FLIP, FASC-FADD2-FLIP2, FASC-FADD3-FLIP2, FASC-FADD-
CASP8, FASC-FADD-FLIP, CASP8, FLIP, FASC-FADD3-CASP83, FASC-FADD3-CASP82-
FLIP, FASC-FADD3-CASP8-FLIP2, FASC-FADD3-FLIP3, CASP8
P41
2 , CASP8
∗
2, CASP3,
CASP8∗2-CASP3, CASP3
∗,
CASP8∗2-Bid, tBid, Bid, Bax, tBid-Bax, tBid-Bax2, Smac, Smac
∗, Cyto.c, Cyto.c∗, XIAP,
Smac∗-XIAP, Apaf, Cyto.c∗-Apaf-ATP, CASP9, Cyto.c∗-Apaf-ATP-CASP9, Cyto.c∗-Apaf-
ATP-CASP92, CASP9
∗, CASP9∗-CASP3, CASP9-XIAP, CASP3∗-XIAP, Bcl2, Bcl2-Bax,
Bcl2-tBid}.2
– The set of labels, L = {e, s, c,m, n}, can also be used to identify the different compartments
where the signalling transduction takes place, namely, the environment (e), the cell surface
(s), the cytoplasm (c), the mitochondria (m), and the nucleus (n).
– In the membrane structure µ = [1[2[3[4 ]4[5 ]5]3]2]1, the compartments are represented. The
compartments 1, 2, 3, and 4 can be labeled respectively with e, s, c, m, and n.
– Mi = {wi, li} where the multiset wi represents the initial amount of molecules in the com-
partment and li is the label associated with the compartment. For Example:
• l1 = e and M1 = {FASL
301}
• l2 = s and M2 = {FAS
602}
• l3 = c and M3 = {FADD
10038, CASP820071, FLIP48779, CASP3120442, Bid15055,
Bax50182, XIAP18066, Apaf60221, ATP6022141 CASP912044, Vpr700}
• l4 = m and M4 = { Smac
60221, Cyto.c60221 Bcl2451661}
• l5 = n and M5 = { HIVRNA
2}
– R1, R2, R3, R4, and R5 are the sets of rules associated with the environment, cell surface,
cytoplasm, mitochondria, and the nucleus. These rules represent the chemical reactions that
take place in each compartment or region of the cell.
• R1 = {r1}
• R2 = {r2, r4, r6, r8, r10, r11, r12, r14, r16, r17, r18, r20, r22, r24, r26, r28, r30, r32, r34,
r36, r38, r40, r42, r44, r46, r48, r50, r52, r54, r56, r58, r60, r62, r63, r64, r65, r66}
• R3 = {r3, r5, r7, r9, r11, r13, r15, r17, r19, r21, r23, r25, r27, r29, r31, r33, r35, r37, r39,
r41, r43, r45, r47, r49, r51, r53, r55, r57, r59, r61, r67, r68, r69, r70, r71, r72, r73,
r74, r75, r76, r77, r78, r79, r80, r81, r82, r83, r84, r85, r86, r87, r88, r89, r90, r91,
r92, r93, r94, r95, r96r98, r99, r100, r101, r102, r103, r104, r105, r106}
• R4 = {r97}
• R5 = {r107, r108, r109, r110}
2 Smac is an abbreviation for second mithocondria-derived activator of caspase.
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We list the four sets of rules we simulated, which are based upon the apoptosis pathway.
Each set incorporates a mechanism for Bcl2 involvement in the inhibition of apoptosis.
label rule rate
r1 : FASL[ FAS ]s → [ FASC ]s k1f
r2 : [ FASC ]s → FASL[ FASC ]s k1r
r3 : FASC[ FADD ]c → FASC : FADD[ ]c k2f
r4 : FASC : FADD[ ]c → FASC[ FADD ]c k2r
r5 : FASC : FADD[ FADD ]c → FASC : FADD2[ ]c k2f
r6 : FASC : FADD2[ ]c → FASC : FADD[ FADD ]c k2r
r7 : FASC : FADD2[ FADD ]c → FASC : FADD3[ ]c k2f
r8 : FASC : FADD3[ ]c → FASC : FADD2[ FADD ]c k2r
r9 : FASC : FADD2 : CASP8[ FADD ]c → FASC : FADD3 : CASP8[ ]c k2f
r10 : FASC : FADD3 : CASP8[ ]c → FASC : FADD2 : CASP8[ FADD ]c k2r
r11 : FASC : FADD2 : FLIP [ FADD ]c → FASC : FADD3 : FLIP [ ]c k2f
r12 : FASC : FADD3 : FLIP [ ]c → FASC : FADD2 : FLIP [ FADD ]c k2r
r13 : FASC : FADD2 : CASP82[ FADD ]c → FASC : FADD3 : CASP82[ ]c k2f
r14 : FASC : FADD3 : CASP82[ ]c → FASC : FADD2 : CASP82[ FADD ]c k2r
r15 : FASC : FADD2 : CASP8 : FLIP [ FADD ]c → FASC : FADD3 : CASP8 : FLIP [ ]c k2f
r16 : FASC : FADD3 : CASP8 : FLIP [ ]c → FASC : FADD2 : CASP8 : FLIP [ FADD ]c k2r
r17 : FASC : FADD2 : FLIP2[ FADD ]c → FASC : FADD3 : FLIP2[ ]c k2f
r18 : FASC : FADD3 : FLIP2[ ]c → FASC : FADD2 : FLIP2[ FADD ]c k2r
r19 : FASC : FADD : CASP8[ FADD ]c → FASC : FADD2 : CASP8[ ]c k2f
r20 : FASC : FADD2 : CASP8[ ]c → FASC : FADD : CASP8[ FADD ]c k2r
r21 : FASC : FADD : FLIP [ FADD ]c → FASC : FADD2 : FLIP [ ]c k2f
r22 : FASC : FADD2 : FLIP [ ]c → FASC : FADD : FLIP [ FADD ]c k2r
r23 : FASC : FADD3[ CASP8 ]c → FASC : FADD3 : CASP8[ ]c k2f
r24 : FASC : FADD3 : CASP8[ ]c → FASC : FADD3[ CASP8 ]c k2r
r25 : FASC : FADD3[ FLIP ]c → FASC : FADD3 : FLIP [ ]c k3f
r26 : FASC : FADD3 : FLIP [ ]c → FASC : FADD3[ FLIP ]c k3r
r27 : FASC : FADD3 : CASP8[ CASP8 ]c → FASC : FADD3 : CASP82[ ]c k3f
r28 : FASC : FADD3 : CASP82[ ]c → FASC : FADD3 : CASP8[ CASP8 ]c k3r
r29 : FASC : FADD3 : CASP8[ FLIP ]c → FASC : FADD3 : CASP8 : FLIP [ ]c k3f
r30 : FASC : FADD3 : CASP8 : FLIP [ ]c → FASC : FADD3 : CASP8[ FLIP ]c k3r
r31 : FASC : FADD3 : FLIP [ CASP8 ]c → FASC : FADD3 : CASP8 : FLIP [ ]c k3f
r32 : FASC : FADD3 : CASP8 : FLIP [ ]c → FASC : FADD3 : FLIP [ CASP8 ]c k3r
r33 : FASC : FADD3 : FLIP [ FLIP ]c → FASC : FADD3 : FLIP2[ ]c k3f
r34 : FASC : FADD3 : FLIP2[ ]c → FASC : FADD3 : FLIP [ FLIP ]c k3r
r35 : FASC : FADD3 : CASP82[ CASP8 ]c → FASC : FADD3 : CASP83[ ]c k3f
r36 : FASC : FADD3 : CASP83[ ]c → FASC : FADD3 : CASP82[ CASP8 ]c k3r
r37 : FASC : FADD3 : CASP82[ FLIP ]c → FASC : FADD3 : CASP82 : FLIP [ ]c k3f
r38 : FASC : FADD3 : CASP82 : FLIP [ ]c → FASC : FADD3 : CASP82[ FLIP ]c k3r
r39 : FASC : FADD3 : CASP8 : FLIP [ CASP8 ]c → FASC : FADD3 : CASP82 : FLIP [ ]c k3f
r40 : FASC : FADD3 : CASP82 : FLIP [ ]c → FASC : FADD3 : CASP8 : FLIP [ CASP8 ]c k3r
r41 : FASC : FADD3 : CASP8 : FLIP [ FLIP ]c → FASC : FADD3 : CASP8 : FLIP2[ ]c k3f
r42 : FASC : FADD3 : CASP8 : FLIP2[ ]c → FASC : FADD3 : CASP8 : FLIP [ FLIP ]c k3r
r43 : FASC : FADD3 : FLIP2[ CASP8 ]c → FASC : FADD3 : CASP8 : FLIP2[ ]c k3f
r44 : FASC : FADD3 : CASP8 : FLIP2[ ]c → FASC : FADD3 : FLIP2[ CASP8 ]c k3r
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r45 : FASC : FADD3 : FLIP2[ FLIP ]c → FASC : FADD3 : FLIP3[ ]c k3f
r46 : FASC : FADD3 : FLIP3[ ]c → FASC : FADD3 : FLIP2[ FLIP ]c k3r
r47 : FASC : FADD2[ CASP8 ]c → FASC : FADD2 : CASP8[ ]c k3f
r48 : FASC : FADD2 : CASP8[ ]c → FASC : FADD2[ CASP8 ]c k3r
r49 : FASC : FADD2[ FLIP ]c → FASC : FADD2 : FLIP [ ]c k3f
r50 : FASC : FADD2 : FLIP [ ]c → FASC : FADD2[ FLIP ]c k3r
r51 : FASC : FADD2 : CASP8[ CASP8 ]c → FASC : FADD2 : CASP82[ ]c k3f
r52 : FASC : FADD2 : CASP82[ ]c → FASC : FADD2 : CASP8[ CASP8 ]c k3r
r53 : FASC : FADD2 : CASP8[ FLIP ]c → FASC : FADD2 : CASP8 : FLIP [ ]c k3f
r54 : FASC : FADD2 : CASP8 : FLIP [ ]c → FASC : FADD2 : CASP8[ FLIP ]c k3r
r55 : FASC : FADD2 : FLIP [ CASP8 ]c → FASC : FADD2 : CASP8 : FLIP [ ]c k3f
r56 : FASC : FADD2 : CASP8 : FLIP [ ]c → FASC : FADD2 : FLIP [ CASP8 ]c k3r
r57 : FASC : FADD2 : FLIP [ FLIP ]c → FASC : FADD2 : FLIP2[ ]c k3f
r58 : FASC : FADD2 : FLIP2[ ]c → FASC : FADD2 : FLIP [ FLIP ]c k3r
r59 : FASC : FADD[ CASP8 ]c → FASC : FADD : CASP8[ ]c k3f
r60 : FASC : FADD : CASP8[ ]c → FASC : FADD[ CASP8 ]c k3r
r61 : FASC : FADD[ FLIP ]c → FASC : FADD : FLIP [ ]c k3f
r62 : FASC : FADD : FLIP [ ]c → FASC : FADD[ FLIP ]c k3r
r63 : FASC : FADD2 : CASP82[ ]c → FASC : FADD2[ CASP8
P41
2 ]c k4
r64 : FASC : FADD3 : CASP83[ ]c → FASC : FADD3 : CASP8[ CASP8
P41
2 ]c k4
r65 : FASC : FADD3 : CASP82 : FLIP [ ]c → FASC : FADD3 : FLIP [ CASP8
P41
2 ]c k4
r66 : FASC : FADD3 : CASP82[ ]c → FASC : FADD3[ CASP8
P41
2 ]c k4
r67 : [ CASP8
P41
2 ]c → [ CASP8
∗
2 ]c k5
r68 : [ CASP8
∗
2, CASP3 ]c → [ CASP8
∗
2 : CASP3 ]c k6f
r69 : [ CASP8
∗
2 : CASP3 ]c → [ CASP8
∗
2, CASP3 ]c k6r
r70 : [ CASP8
∗
2, CASP3
∗ ]c → [ CASP8
∗
2 : CASP3 ]c k7
r71 : [ CASP8
∗
2
, Bid ]c → [ CASP8
∗
2
: Bid ]c k8f
r72 : [ CASP8
∗
2 : Bid ]c → [ CASP8
∗
2, Bid ]c k8r
r73 : [ CASP8
∗
2, tBid ]c → [ CASP8
∗
2 : Bid ]c k7
r74 : [ tBid,Bax ]c → [ tBid : Bax ]c k9f
r75 : [ tBid : Bax ]c → [ tBid,Bax ]c k9r
r76 : [ tBid : Bax,Bax ]c → [ tBid : Bax2 ]c k9f
r77 : [ tBid : Bax2 ]c → [ tBid : Bax,Bax ]c k9r
r78 : tBid : Bax2[ Smac ]m → Smac
∗[ ]m k10
r79 : tBid : Bax2[ Cyto.c ]m → Cyto.c
∗[ ]m k10
r80 : [ Smac
∗,XIAP ]c → [ Smac
∗ : XIAP ]c k11f
r81 : [ Smac
∗ : XIAP ]c → [ Smac
∗,XIAP ]c k11r
r82 : [ Cyto.c
∗, Apaf,ATP ]c → [ Cyto.c
∗ : Apaf : ATP ]c k12f
r83 : [ Cyto.c
∗ : Apaf : ATP ]c → [ Cyto.c
∗, Apaf,ATP ]c k12r
r84 : [ Cyto.c
∗ : Apaf : ATP,CASP9 ]c → [ Cyto.c
∗ : Apaf : ATP : CASP9 ]c k13f
r85 : [ Cyto.c
∗ : Apaf : ATP : CASP9 ]c → [ Cyto.c
∗ : Apaf : ATP,CASP9 ]c k13r
r86 : [ Cyto.c
∗ : Apaf : ATP : CASP9, CASP9 ]c → [ Cyto.c
∗ : Apaf : ATP : CASP92 ]c k14f
r87 : [ Cyto.c
∗ : Apaf : ATP : CASP92 ]c → [ Cyto.c
∗ : Apaf : ATP : CASP9, CASP9 ]c k14r
r88 : [ Cyto.c
∗ : Apaf : ATP : CASP92 ]c → [ Cyto.c
∗ : Apaf : ATP : CASP9, CASP9∗ ]c k15
r89 : [ CASP9
∗, CASP3 ]c → [ CASP9
∗ : CASP3 ]c k16f
r90 : [ CASP9
∗ : CASP3 ]c → [ CASP9
∗, CASP3 ]c k16r
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r91 : [ CASP9
∗ : CASP3 ]c → [ CASP9
∗, CASP3∗ ]c k17
r92 : [ CASP9,XIAP ]c → [ CASP9 : XIAP ]c k18f
r93 : [ CASP9 : XIAP ]c → [ CASP9,XIAP ]c k18r
r94 : [ CASP3
∗,XIAP ]c → [ CASP3
∗ : XIAP ]c k19f
r95 : [ CASP3
∗ : XIAP ]c → [ CASP3
∗,XIAP ]c k19r
r96 : Bax[ Bcl2 ]m → [ Bcl2 : Bax ]m k20f
r97 : [ Bcl2 : Bax ]m → Bax[ Bcl2 ]m k20r
r98 : tBid[ Bcl2 ]m → [ Bcl2 : tBid ]m k20f
r99 : [ Bcl2 : tBid ]m → tBid[ Bcl2 ]m k20r
r100 : V pr[ ]m → V pr[ Bcl2 ]m k21f
r101 : [ V pr,Bax ]c → [ V pr ]c k22f
r102 : [ Tat ]c → [ Tat, Casp8 ]c k23f
r103 : [ Tat ]c → [ Tat,Bcl2 ]c k24f
r104 : [ Tat,Bcl2 ]c → [ Tat ]c k25f
r105 : [ HIV Protease,Casp8 ]c → [ HIV Protease,Casp8∗ ]m k26f
r106 : HIV Protease[ Bcl2 ]m → HIV Protease[ ]m k27f
r107 : HIV RNA[ ]n → [ HIV RNA ]m k28f
r108 : [ HIV RNA ]n → V pr[ HIV RNA ]m k29f
r109 : HIV RNA[ ]n → Tat[ HIV RNA ]m k30f
r110 : HIV RNA[ ]n → HIV Protease[ HIV RNA ]m k31f
The deterministic kinetic constants (reaction rates) mentioned in the previous table are
given in the following; we refer the interested reader to [19] for more details about the rates and
references for their estimation.
k1f = 9.09E − 05 nM
−1s−1
k1r = 1.00E − 04 s
−1
k2f = 5.00E − 04 nM
−1s−1
k2r = 0.2 s
−1
k3f = 3.50E − 03 nM
−1s−1
k3r = 0.018 s
−1
k4 = 0.3 s
−1
k5 = 0.1 s
−1
k6f = 1.00E − 05 nM
−1s−1
k6r = 0.06 s
−1
k7 = 0.1 s
−1
k8f = 5.00E − 03 nM
−1s−1
k8r = 0.005 s
−1
k9f = 2.00E − 04 nM
−1s−1
k9r = 0.02 s
−1
k10 = 1.00E − 03 nM
−1s−1
k11f = 7.00E − 03 nM
−1s−1
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k11r = 2.21E − 03 s
−1
k12f = 2.78E − 07 nM
−1s−1 nM−1
k12r = 5.70E − 03 s
−1
k13f = 2.84E − 04 nM
−1s−1
k13r = 0.07493 s
−1
k14f = 4.41E − 04 nM
−1s−1
k14r = 0.1 s
−1
k15 = 0.7 s
−1
k16f = 1.96E − 05 nM
−1s−1
k16r = 0.05707 s
−1
k17 = 4.8 s
−1
k18f = 1.06E − 04 nM
−1s−1
k18r = 1.00E − 03 s
−1
k19f = 2.47E − 03 nM
−1s−1
k19r = 2.40E − 03 s
−1
k20f = 2.00E − 03 nM
−1s−1
k20r = 0.02s
−1
k21f = 0.0006s
−1
k22f = 0.000041nM−1s
−1
k23f = 0.0023s
−1
k24f = 0.00004s
−1
k25f = 0.00000523nM
−1s−1
k26f = 0.0000050005nM
−1s−1
k27f = 0.00000523nM−1s
−1
k28f = 0.000046294nM−1s
−1
k29f = 0.000578703711nM−1s
−1
k30f = 0.000578703709nM−1s
−1
k31f = 0.00057870371nM−1s
−1
16
10 10.5 110
1
2
3
4
5
Time (Minutes)
N
um
be
r o
f M
ol
ec
ul
es
Casp8* binds Procasp3
0 6 12 18 24 30 36 42 48 54 60 66 720
1
2
3
4
5
Time (Hour)
N
um
be
r o
f M
ol
ec
ul
es
Casp8* binds Procasp3
24 24.5 25 25.5 260
1
2
3
4
5
Time (Hour)
N
um
be
r o
f M
ol
ec
ul
es
Casp9* binds Procasp3
0 6 12 18 24 30 36 42 48 54 60 66 720
1
2
3
4
5
Time (Hour)
N
um
be
r o
f M
ol
ec
ul
es
Casp9* binds Procasp3
6 6.5 7 7.5 80
1
2
3
4
5
Time (Minutes)
N
um
be
r o
f M
ol
ec
ul
es
Casp8* binds Procasp3
6 6.5 7 7.5 80
1
2
3
4
5
Time (Minutes)
N
um
be
r o
f M
ol
ec
ul
es
Casp8* binds Procasp3
17 17.5 180
1
2
3
4
5
Time (Hour)
N
um
be
r o
f M
ol
ec
ul
es
Casp9* binds Procasp3
17 17.5 180
1
2
3
4
5
Time (Hour)
N
um
be
r o
f M
ol
ec
ul
es
Casp9* binds Procasp3
